IPO Boutique Research, Color & More Information for Subscribers
This content is restricted to IPO Boutique Subscribers Username or E-mail: Become a Subscriber Disclaimer IPO Boutique aggregates information on public companies and private companies, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual[…]
IPO BOUTIQUE CLIENTS and IPO BOUTIQUE SECONDARY ALERTS CLIENTS received ALL this information to their inbox on a REAL TIME basis. If having real-time alerts for secondary offerings would be an advantage to you, inquire about a subscription today! Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis.[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Digital Realty Trust Symbol: DLR Price: Last trade $68.42 Trade Date: 7/15 Shares: 10.5 million Underwriter(s) BofA Merrill Lynch, Morgan Stanley,[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. To subscribe to his secondary ratings, click here. Company: ServiceMaster Global Holdings, Inc.
IPOBoutique is a full service syndicate boutique. We not only relay color and advisories on IPOs, but we rate every secondary that hits the tape on a nightly basis. We also provide a track record for secondary’s we have issued a ‘BUY’ rating to. Company: Alnylam
It’s Thursday, so why not indulge the ‘throw-back’ nature of the day and look at a pair of biotechs from January 2014 that started the Healthcare crazy in the IPO market: Dicerna Pharmaceuticals (Nasdaq: DRNA) and Ultragenyx Pharmaceuticals (Nasdaq: RARE). These were two of 102 biotech deals that came to market in 2014 but the[…]